Intercept Pharmaceuticals (ICPT) Upgraded by ValuEngine to “Buy”

ValuEngine upgraded shares of Intercept Pharmaceuticals (NASDAQ:ICPT) from a hold rating to a buy rating in a research note released on Friday morning.

Several other brokerages have also issued reports on ICPT. BidaskClub raised shares of Intercept Pharmaceuticals from a buy rating to a strong-buy rating in a report on Tuesday, October 2nd. Zacks Investment Research raised shares of Intercept Pharmaceuticals from a hold rating to a buy rating and set a $113.00 price target on the stock in a report on Tuesday, November 13th. Laidlaw lowered shares of Intercept Pharmaceuticals from a buy rating to a hold rating and boosted their price target for the company from $90.00 to $95.00 in a report on Friday, August 3rd. Roth Capital initiated coverage on shares of Intercept Pharmaceuticals in a report on Wednesday, September 12th. They issued a buy rating and a $192.00 price target on the stock. Finally, Cantor Fitzgerald set a $69.00 price target on shares of Intercept Pharmaceuticals and gave the company a hold rating in a report on Thursday, August 2nd. Seven analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus target price of $143.06.

Shares of Intercept Pharmaceuticals stock opened at $111.07 on Friday. The firm has a market capitalization of $3.29 billion, a price-to-earnings ratio of -7.72 and a beta of -1.08. The company has a debt-to-equity ratio of 3.83, a quick ratio of 5.98 and a current ratio of 5.98. Intercept Pharmaceuticals has a 52-week low of $51.05 and a 52-week high of $133.74.

Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its quarterly earnings results on Wednesday, October 31st. The biopharmaceutical company reported ($2.18) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($2.65) by $0.47. The firm had revenue of $47.00 million for the quarter, compared to analyst estimates of $48.24 million. Intercept Pharmaceuticals had a negative net margin of 202.93% and a negative return on equity of 645.54%. The business’s revenue for the quarter was up 13.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($2.89) EPS. Analysts expect that Intercept Pharmaceuticals will post -10 EPS for the current fiscal year.

In other news, CEO Mark Pruzanski sold 50,000 shares of the company’s stock in a transaction dated Friday, November 16th. The shares were sold at an average price of $101.07, for a total value of $5,053,500.00. Following the sale, the chief executive officer now owns 589,199 shares of the company’s stock, valued at approximately $59,550,342.93. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider David Shapiro sold 759 shares of the company’s stock in a transaction dated Friday, October 5th. The stock was sold at an average price of $110.65, for a total transaction of $83,983.35. Following the completion of the sale, the insider now directly owns 39,152 shares in the company, valued at approximately $4,332,168.80. The disclosure for this sale can be found here. In the last ninety days, insiders sold 61,101 shares of company stock worth $6,230,628. 4.90% of the stock is owned by insiders.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Strs Ohio acquired a new position in Intercept Pharmaceuticals during the 3rd quarter worth about $126,000. Chicago Equity Partners LLC acquired a new position in Intercept Pharmaceuticals during the 3rd quarter worth about $215,000. GWM Advisors LLC acquired a new position in Intercept Pharmaceuticals during the 3rd quarter worth about $220,000. Tocqueville Asset Management L.P. acquired a new position in Intercept Pharmaceuticals during the 2nd quarter worth about $252,000. Finally, Sheaff Brock Investment Advisors LLC acquired a new position in Intercept Pharmaceuticals during the 2nd quarter worth about $264,000. 63.20% of the stock is currently owned by institutional investors and hedge funds.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the United States, Europe, and Canada. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR).

Read More: What are the components of an earnings report?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply